Market Overview - The Hong Kong stock market experienced fluctuations, with the Hang Seng Index closing at 23,831 points, down 145 points or 0.61% [1] - The US stock market saw declines across major indices, with the Dow Jones falling by 427.09 points or 0.90% [2] - Southbound funds maintained a net inflow of 121.9 billion HKD in November, indicating continued interest in Hong Kong stocks [3] Sector Performance - The materials sector, particularly non-ferrous metals, led the gains in the Hong Kong market, with notable increases in stock prices for companies like Sunny Optical Technology, which rose by 6.2%, and Zijin Mining, which increased by 5.3% [1][5] - In the US market, technology stocks faced profit-taking pressure, particularly in AI-related stocks, contributing to the overall market decline [2] Investment Opportunities - The report emphasizes the importance of technological self-reliance as a core theme for future performance in the Hong Kong market, suggesting that leading companies in AI, semiconductors, and industrial software may present long-term growth opportunities [3] - Specific recommendations include focusing on sectors with lower valuations and higher dividends, as well as companies benefiting from anticipated Federal Reserve interest rate cuts [3] Company Highlights - XPeng Motors reported a 19% year-on-year increase in vehicle deliveries for November, totaling 36,728 units, and a cumulative delivery of 391,937 units for the year, reflecting a 156% increase [9] - Alibaba, ZTE, and Meituan were among the top net purchases by southbound funds, indicating strong investor interest in these companies [9] Stock Performance - The Hang Seng Index and its sub-indices showed varied performance over the past month, with the Hang Seng Technology Index up by 0.8% [16] - Notable stock performances include Tencent Holdings, which saw a 1.3% increase, and Alibaba, which rose by 2.2% [16]

Core Viewpoint - Southbound funds have significantly increased their holdings in Jinxin Reproductive Medicine (01951.HK), indicating strong investor interest in the company [1] Group 1: Shareholding Changes - On December 1, southbound funds increased their holdings by 2.9025 million shares, representing a 0.20% change [2] - Over the past five trading days, there has been a cumulative net increase of 27.119 million shares held by southbound funds [1][2] - In the last 20 trading days, southbound funds have increased their holdings on 15 occasions, with a total net increase of 48.7178 million shares [1] Group 2: Current Holdings - As of now, southbound funds hold a total of 1.485 billion shares of Jinxin Reproductive Medicine, accounting for 53.83% of the company's issued ordinary shares [1][2] Group 3: Company Overview - Jinxin Reproductive Medicine is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers a range of services including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and sales of medical consumables and equipment, mainly in China and the United States [2]

Core Viewpoint - The company, Jinxin Reproductive Medicine (01951), has announced a share buyback program, indicating that its current trading price does not reflect its intrinsic value or actual business prospects [1] Group 1: Share Buyback Announcement - The company is authorized to repurchase up to 274 million shares, which represents 10% of the total shares issued as of the date of the annual general meeting, excluding treasury shares [1] - The board of directors has resolved to utilize the buyback authorization to repurchase shares in the open market at a total price of no less than HKD 100 million [1] - The proposed share buyback is seen as a demonstration of the company's confidence in its business development prospects [1] Group 2: Financial Position - The company believes that its existing financial resources are sufficient to support the proposed share buyback while maintaining a robust financial position [1]

Core Viewpoint - The company, Jinxin Reproductive Medicine (01951), has announced a share buyback plan, indicating that its current trading price does not reflect its intrinsic value or actual business prospects [1] Group 1: Share Buyback Details - The company is authorized to repurchase up to 274 million shares, which represents 10% of the total shares issued as of the date of the annual general meeting, excluding treasury shares [1] - The board has resolved to utilize the buyback authorization to repurchase shares in the open market for a total price of no less than HKD 100 million [1] Group 2: Rationale and Financial Position - The company believes that the proposed share buyback will demonstrate its confidence in its business development prospects [1] - The existing financial resources of the company are deemed sufficient to support the implementation of the proposed share buyback while maintaining a robust financial position [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 所產生或因依賴該等內容而引致的任何損失承擔任何責任。 Jinxin Fertility Group Limited - 1 - 1951 * 自願公告 建議於市場上購回股份 本公告乃由錦欣生殖醫療集團有限公司*（「本公司」）自願刊發。 茲提述本公司日期為2025年6月26日的公告，內容有關（其中包括）本公司股東於本公司於 2025年6月26日舉行的股東週年大會（「股東週年大會」）授出的購回本公司股份（「股份」）的 一般授權（「購回授權」）。根據購回授權，本公司獲准於香港聯合交易所有限公司（「聯交 所」）購回最多274,470,604股股份，佔於股東週年大會日期已發行股份（不包括庫存股份） 總數的10%。 本公司認為，股份目前的交易價格並未反映其內在價值或本公司的實際業務前景。因 此，本公司董事會（「董事會」）已議決利用購回授權，以不時在公開市場上按不少於1億港 元的總價格購回股份（「建議股份購回」）。本公司認為，建議股份購回將展現本公司對其 自身業務發展前 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 錦欣生殖醫療集團有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01951 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊 ...

Group 1 - Southbound funds increased their holdings in Jinxin Reproductive Medicine (01951.HK) by 6.2985 million shares on November 26, 2025, marking a 0.43% change [1][2] - Over the past five trading days, there have been five days of net increases in holdings, totaling 20.795 million shares [1][2] - In the last 20 trading days, there were 13 days of net increases, amounting to 31.1263 million shares [1][2] Group 2 - As of now, southbound funds hold 1.474 billion shares of Jinxin Reproductive Medicine, representing 53.44% of the company's total issued ordinary shares [1][2] - Jinxin Reproductive Medicine is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers a range of services including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and sales of medical consumables and equipment, mainly in China and the United States [2]

Core Insights - Southbound funds increased their holdings in Jinxin Reproductive Medicine (01951.HK) by 611,000 shares on November 24, 2025, marking a consistent trend of net increases over recent trading days [1] - Over the past 5 trading days, there has been a cumulative net increase of 11.76 million shares, while in the last 20 trading days, the total net increase reached 12.71 million shares [1] - As of now, southbound funds hold 1.458 billion shares of Jinxin Reproductive Medicine, accounting for 52.84% of the company's total issued ordinary shares [1] Summary by Category Trading Activity - On November 24, 2025, total shares held reached 1.458 billion, with a change of 611,000 shares, reflecting a 0.04% increase [2] - On November 21, 2025, total shares held were 1.457 billion, with a change of 630,000 shares, also a 0.04% increase [2] - On November 20, 2025, total shares held were 1.456 billion, with a change of 3.183 million shares, indicating a 0.22% increase [2] - On November 19, 2025, total shares held were 1.453 billion, with a change of 3.168 million shares, also a 0.22% increase [2] - On November 18, 2025, total shares held were 1.450 billion, with a change of 4.170 million shares, reflecting a 0.29% increase [2] Company Overview - Jinxin Reproductive Medicine is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and maternal and pediatric medical services [2] - Jinxin Reproductive Medicine operates mainly in China and the United States [2]

Core Insights - Southbound funds increased their holdings in Jinxin Reproductive Medicine (01951.HK) by 3.168 million shares on November 19, 2025, marking a 0.22% increase in total shares held [1][2] - Over the past five trading days, there have been four days of net increases in holdings, totaling 6.8563 million shares [1] - In the last twenty trading days, there were ten days of net increases, amounting to 9.4968 million shares [1] - As of now, southbound funds hold 1.453 billion shares of Jinxin Reproductive Medicine, representing 52.69% of the company's total issued ordinary shares [1] Company Overview - Jinxin Reproductive Medicine Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and maternal and pediatric medical services [2] - Jinxin operates mainly in China and the United States, also engaging in the sale of medical consumables and equipment [2]

JINXIN FERTILITY GROUP LIMITED (a company incorporated in the Cayman Islands with limited liability) SHARE SCHEME PREAMBLE 1. DEFINITIONS 1.1 In this Scheme, the following expressions have the following meanings: Acknowledgement Form shall have the meaning as defined in Rule 6.5; Actual Selling Price means the actual price at which the Option Shares or Restricted Shares are sold (net of brokerage, stamp duty, Stock Exchange trading fee, SFC transaction levy and any other applicable costs) on vesting of an A ...